Letters to the Editor

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna
Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece
Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
University of Medicine and Pharmacy "Carol Davila", Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic
1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary
National Research Center for Haematology, Moscow, Russia
Oncopeptides AB, Stockholm, Sweden
Oncopeptides AB, Stockholm, Sweden
Oncopeptides AB, Stockholm, Sweden
Oncopeptides AB, Stockholm, Sweden
Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain
Dana-Farber Cancer Institute, Boston, MA
Erasmus MC Cancer Institute, Rotterdam
Haematologica Early view Feb 29, 2024 https://doi.org/10.3324/haematol.2023.284635